SlideShare a Scribd company logo
1 of 32
EVIDENCE-BASED DECISION MAKING
IN GLAUCOMA MANAGEMENT
ROLE OF TARGET PRESSURE AND
CENTRAL CORNEAL THICKNESS
By
Dr Nkiru Kizor-Akaraiwe
@ South-East Glaucoma symposium
Feb, 2017
Background
• IOP is a very important risk factor
• IOP is the only modifiable risk factor
• Aim of glaucoma Rx is to maintain visual
function(by reducing the IOP to such a level that
glaucomatous damage will not continue) while
maintaining quality of life at a sustainable cost.
Treatment Principles & Options. EGS Guidelines, Edition 4. Pg 131-138
Evidence – Based Care for IOP
reduction in glaucoma Mx……
The Collaborative Normal-Tension Glaucoma
Study
Collaborative Normal-Tension Glaucoma Study Group(CNGTS).
Effectiveness of intraocular pressure reduction in the treatment of normal-
tension glaucoma. Am J Ophthalmol 1998;126:498-505
Evidence – Based Care for IOP
reduction in glaucoma Mx……
The Advanced Glaucoma Intervention Study
Collaborative Normal-Tension Glaucoma Study Group(CNGTS). Effectiveness of
intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J
Ophthalmol 1998;126:498-505
Evidence – Based Care for IOP
reduction in glaucoma Mx……
The Collaborative Initial Glaucoma Treatment
Study
Musch DC, Gillespie BW, Niziol LM, et al; the CIGTS Study Group. Intraocular pressure
control and long-term visual field loss in the Collaborative Initial Glaucoma
Treatment Study. Ophthalmology. 2011;118:1766-1773.
Evidence – Based Care for IOP
reduction in glaucoma Mx……
The Ocular Hypertension Treatment Study
Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension
Treatment Study: a randomized trial determines that topical ocular
hypotensive medication delays or prevents the onset of primary open-
angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713.
Evidence – Based Care for IOP
reduction in glaucoma Mx……
Early Manifest Glaucoma Trial
Heijl A, Leske MC, Bengtsson B, et al; Early Manifest Glaucoma Trial Group.
Reduction of intraocular pressure and glaucoma progression: results from the
Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268-1279.
What is Target pressure?
• Target pressure is defined as the upper limit of
IOP level at which further glaucomatous optic
neuropathy is unlikely to occur inorder to
maintain patient’s vision related quality of life.
• Target pressure is the IOP goal
• 1st introduced in 1989 by Paul F. Palmberg
Treatment Principles & Options. EGS Guidelines, Edition 4. Pg 131-138
Benefits of Target pressure in Mx
1. Gives the Physician a focus(goal) in care (No
‘continue Rx’)
2. Gives patient a focus and wish to keep their
follow-up appointments
3. Gives the patients a goal that makes them take
responsibility for their care & progress
4. Helps patients to appreciate success and non-
success and more agreeable to a change of
therapy (including surgery)
Inder Paul Singh. Setting Target Pressures. Glaucoma Today. September/October 2015
Setting Target IOP – Factors to consider
Factors to Consider Low Target IOP Higher Target IOP
1. Glaucoma
Damage
Advanced Early
2. Life
expectancy
Long Short
3. Baseline
(Untreated) IOP
Low High
4. Additional Risk
factors
Yes No
5. Rate of
Progression
Fast Slow
6. CCT Thin Thick
Treatment Principles & Options. EGS Guidelines, Edition 4. Pg 131-138
Risk factors for progression that may modify the initial target
IOP range include the following:
• Presence and severity of damage to fellow eye
• Rapid rate of progression of damage to fellow eye
• Family history of or genetic mutation predisposing to early
onset disease or severe disease, or both
• African ancestry
• Vascular risk factors: disc hemorrhage, nocturnal
hypotension, migraine, Raynaud's disease, diabetes
mellitus, previous vein occlusion
• Large fluctuation or instability in IOP (e.g., IOP spikes,
pseudoexfoliation syndrome)
• Poor follow-up
• Axial myopia (speculative)
Damji KF, Behki R, Wang L, for the Target IOP Workshop participants. Canadian
perspectives in glaucoma management: setting target intraocular pressure range. Can J
Ophthalmol 2003;38:189-197.
Setting Target IOP
– Numbers or Percentages?
Stage of
Glaucoma
Evidence IOP percentage
reduction
Range of IOP Findings from study
OHTN OHTS ≥20% 18-21mmHg 5% progression at
20% reduction
Mild Glaucoma EMGT
CIGTS
≥25% < 18mmHg 30% reduction no
progression in 7yrs
Moderate
Glaucoma
CIGTS
AGIS
≥30% 14-16mmHg
Severe
Glaucoma
AGIS ≥35% 10- 12mmHg IOP average =12;no
progression x 14yrs
Principle for Setting Target pressure:
IOP
TgP = ------------------------------------------------
Level of function loss + RoP + Factors
Treatment Principles & Options. EGS Guidelines, Edition 4. Pg 131-138
Target pressure ….Points to note
• Always note down in the folder the set target
pressure with date.
• Target pressure is set separately for each eye
• Refer to it each visit – result of visit’s evaluation.
• Not static - change constantly depending on
whether the glaucoma is stable or shows signs of
progression.
Central Corneal Thickness
In
Glaucoma Management
Background
• IOP is a very important risk factor
• IOP is the only modifiable risk factor
• IOP is measured by either indenting or
applanating the central cornea therefore its
thickness will affect the reading.
Treatment Principles & Options. EGS Guidelines, Edition 4. Pg 131-138
Evidence – Based Care for CCT
measurement in glaucoma Mx……
The Ocular Hypertension Treatment Study
Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension
Treatment Study: a randomized trial determines that topical ocular
hypotensive medication delays or prevents the onset of primary open-angle
glaucoma. Arch Ophthalmol. 2002;120(6):701-713.
CCT Values
• The normal distribution of CCT is 540µm ± 30
• Blacks generally have thinner corneas
• Screening population of normals @ The Eye
Specialists hospital, Enugu, Nigeria = 526µm ± 75
(Range of 458-608)
Rahman ML, Bunce C, Healey PR et al. Commingling analyses of central corneal
thickness and adjusted intraocular pressure in an older Australian population.
Invest Ophthalmol Vis Sci 2010;51(5) 2512-8
CCT differences among patient groups
• The mean central corneal thickness was:
» Controls = 554 µm
» POAG = 550 µm
» NTG = 514 µm - lowest
» OHT = 580 µm
Shah S, Chatterjee A, Mathai M, et al. Relationship between corneal thickness
and measured intraocular pressure in a general ophthalmology clinic.
Ophthalmology. 1999;106:2154-2160.
Copt RP, Thomas R, Mermoud A. Corneal thickness in ocular hypertension,
primary open-angle glaucoma, and normal tension glaucoma. Arch
Ophthalmol. 1999;117:14-16.
Differences among Diff races
Findings:
• Caucasians, Chinese, Filipinos & Hispanics = 0.550mm
> Japanese = 0.531mm
> African Americans = 0.521mm
Central corneal thickness of Caucasians, Chinese, Hispanics, Filipinos,
African Americans, and Japanese in a glaucoma clinic.
Aghaian E1, Choe JE, Lin S, Stamper RL. Ophthalmology 2004 Dec;111(12):2211-9
Why is CCT important?
• A Risk factor
• Misdiagnosis
• Uncertain-target pressure setting
CCT as a Risk Factor
• For development:
The Ocular Hypertension Treatment Study
(OHTS) showed that CCT is an important risk
factor for a change from ocular hypertension
to primary open-angle glaucoma.
Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension
Treatment Study: a randomized trial determines that topical ocular
hypotensive medication delays or prevents the onset of primary open-angle
glaucoma. Arch Ophthalmol. 2002;120(6):701-713.
CCT & POAG development
• Subjects with CCT ≤ 555 µm had 3x greater
risk of developing POAG than
Those with CCT ≥ 588 µm
Gordon MO, Beiser JA, Brandt JD, et al. The ocular hypertension
treatment study: Baseline factors that predict the onset of primary
open-angle glaucoma. Arch Ophthalmol. 2002;120:714-720.
CCT as a Risk Factor
• For progression:
Powerful predictor of risk of glaucoma progression
- Early Manifest Glaucoma Trial (EMGT) with an 11-
year follow-up, CCT was a significant predictive factor
for glaucoma progression
- In a multivariate model study in Advanced glaucoma
pts by Weizer et al that included IOP, CCT was the
most powerful component of the predictive model.
Weizer JS, Stinnett SS, Herndon LW. Central corneal thickness as a risk factor for
advanced glaucoma damage. Paper presented at: Annual Meeting of The Association
for Research in Vision and Ophthalmology; May 5, 2003; Fort Lauderdale, FL.
Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268-1279.Heijl A,
Leske MC, Bengtsson B, et al; Early Manifest Glaucoma Trial Group. Reduction of
intraocular pressure and glaucoma progression
CCT & Progression
Findings:
• Eyes with CCT 520 m had significantly
earlier glaucoma progression though the mean
IOP was less in them.
• Chiseliţă D1, Danielescu C, Gagos-Zaharia O, Gherman C.
Central thickness of the cornea in ocular hypertension and open
angle glaucoma Oftalmologia.2007;51(3):98-103
2. Mis-diagnosis of glaucoma
• Variations in measurement of CCT may lead to
mis-diagnosis of glaucoma.
• Thin CCT  Underestimation of IOP/Target IOP
- Glaucoma patients are missed/suspects
- POAG classified as NTG
• Thick CCT  Overestimation of IOP/ Target IOP
- Normal patients receiving Rx as OHT
- NTG managed as POAG
The role of central corneal thickness in
the diagnosis of glaucoma
Result:
39% of eyes with ocular hypertension were
found to have a corrected IOP of ≤ 21 mmHg.
Thomas R, Korah S, Muliyil J. India J Ophthalmol 2000
Jun;48(2):107-11
3. Uncertain estimation of Target pressure
• Low CCT  wrongly set higher TgP
E.g CCT = 480µm (+4); TgP = 12mmHg instead
of <9mmHg
• High CCT  wrongly set Lower TgP
E.g CCT 590µm (-4); TgP = 12 instead of
<16mmHg
The importance of central corneal thickness
measurements and decision making in general
ophthalmology clinics: a masked observational study
Result:
• CCT and adjusted IOP information led to
different treatment option in 37%(55/152).
- 20.4%(31/152) cases would have been commenced
on additional IOP-lowering medication
- 2.0%(3/152) would have been counseled for
trabeculectomy surgery
- 3.3%(5/152) of the cohort would have been
observed rather than treated
Patwardhan et al; BMC Ophthalmology2008;8:1 DOI: 10.1186/1471-2415-8-1
Central corneal thickness and potential error in
Goldmann applanation tonometry of the
Black African patient suffering from primary open-
angle glaucoma: 340 eyes surveyed.
Findings:
• GAT- affected by an error rate estimated at 69.4%
- 57.6% undervaluation
- 11.8% overvaluation
• Pachymetry is therefore a necessity for the
Black African glaucoma patient requiring IOP
adjustment.
• Fanny et al..J Fr Ophthalmol 2008 Apr;31(4):405-8
Conclusion…
• Target Pressure is the IOP goal set at
beginning that drives the glaucoma care
&
• CCT measurement (Pachymetry) is an
essential part of glaucoma pt’s evaluation for
determining the real target pressure,
predicting risk of development & progression
of disease thereby ensuring individual pt’s
optimal management.
THANK YOU!!!

More Related Content

Similar to CCT and TARGET PRESSURE in Glaucoma Management - Pfizer Symposium.pptx

Glaucoma slides
Glaucoma slidesGlaucoma slides
Glaucoma slidesBapi Das
 
GLAUCOMA MEDICATION.pptx
GLAUCOMA MEDICATION.pptxGLAUCOMA MEDICATION.pptx
GLAUCOMA MEDICATION.pptxSheim Elteb
 
Ocular Hypertension Treatment study (OHTS).pptx
Ocular Hypertension Treatment  study (OHTS).pptxOcular Hypertension Treatment  study (OHTS).pptx
Ocular Hypertension Treatment study (OHTS).pptxRashtriyaSamajseviPa
 
Diabetic retinopathy management an advanced approach gonzalez
Diabetic retinopathy management an advanced approach gonzalezDiabetic retinopathy management an advanced approach gonzalez
Diabetic retinopathy management an advanced approach gonzalezDiopsys, Inc.
 
Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...
Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...
Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...CrimsonpublishersMSOR
 
Normal Tension Glaucoma
Normal Tension GlaucomaNormal Tension Glaucoma
Normal Tension Glaucomaeknath87
 
Anterior Segment Company Showcase - Sensimed AG
Anterior Segment Company Showcase - Sensimed AGAnterior Segment Company Showcase - Sensimed AG
Anterior Segment Company Showcase - Sensimed AGHealthegy
 
Study on correlation between Diabetes mellitus and Central corneal thickness
Study on correlation between Diabetes mellitus and Central corneal thicknessStudy on correlation between Diabetes mellitus and Central corneal thickness
Study on correlation between Diabetes mellitus and Central corneal thicknessiosrjce
 
Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...
Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...
Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...QUESTJOURNAL
 
Dr screening training for nurses 1-diabetic retinopathy screening programs,...
Dr screening training for nurses   1-diabetic retinopathy screening programs,...Dr screening training for nurses   1-diabetic retinopathy screening programs,...
Dr screening training for nurses 1-diabetic retinopathy screening programs,...Riyad Banayot
 
MG comparison, Ocular vs General
MG comparison, Ocular vs GeneralMG comparison, Ocular vs General
MG comparison, Ocular vs GeneralErsifa Fatimah
 
Glaucoma the-silent-thief of sight by Abdulwahab Usman
Glaucoma the-silent-thief of sight by Abdulwahab UsmanGlaucoma the-silent-thief of sight by Abdulwahab Usman
Glaucoma the-silent-thief of sight by Abdulwahab UsmanAbdulwahab Usman
 
Glaucoma suspect,ocular hypertension, steroid induced glaucoma
Glaucoma suspect,ocular hypertension, steroid induced glaucomaGlaucoma suspect,ocular hypertension, steroid induced glaucoma
Glaucoma suspect,ocular hypertension, steroid induced glaucomaBipin Bista
 
Gruber R, I Fetian et al. The Effect of Magnesium on RVP of Patients with NTG...
Gruber R, I Fetian et al. The Effect of Magnesium on RVP of Patients with NTG...Gruber R, I Fetian et al. The Effect of Magnesium on RVP of Patients with NTG...
Gruber R, I Fetian et al. The Effect of Magnesium on RVP of Patients with NTG...Issa Rasheed
 
Glaucoma
GlaucomaGlaucoma
Glaucomanazaika
 

Similar to CCT and TARGET PRESSURE in Glaucoma Management - Pfizer Symposium.pptx (20)

Glaucoma slides
Glaucoma slidesGlaucoma slides
Glaucoma slides
 
GLAUCOMA MEDICATION.pptx
GLAUCOMA MEDICATION.pptxGLAUCOMA MEDICATION.pptx
GLAUCOMA MEDICATION.pptx
 
Ocular Hypertension Treatment study (OHTS).pptx
Ocular Hypertension Treatment  study (OHTS).pptxOcular Hypertension Treatment  study (OHTS).pptx
Ocular Hypertension Treatment study (OHTS).pptx
 
Glaucoma: Preferred Practice Patterns
Glaucoma: Preferred Practice PatternsGlaucoma: Preferred Practice Patterns
Glaucoma: Preferred Practice Patterns
 
Diabetic retinopathy management an advanced approach gonzalez
Diabetic retinopathy management an advanced approach gonzalezDiabetic retinopathy management an advanced approach gonzalez
Diabetic retinopathy management an advanced approach gonzalez
 
Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...
Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...
Selective Laser Trabeculoplasty as a Replacement Therapy in Open Angle Glauco...
 
Normal Tension Glaucoma
Normal Tension GlaucomaNormal Tension Glaucoma
Normal Tension Glaucoma
 
DME management
DME managementDME management
DME management
 
Normal tension glaucoma
Normal tension glaucomaNormal tension glaucoma
Normal tension glaucoma
 
Anterior Segment Company Showcase - Sensimed AG
Anterior Segment Company Showcase - Sensimed AGAnterior Segment Company Showcase - Sensimed AG
Anterior Segment Company Showcase - Sensimed AG
 
Primary Open Angle Glaucoma
Primary Open Angle GlaucomaPrimary Open Angle Glaucoma
Primary Open Angle Glaucoma
 
Study on correlation between Diabetes mellitus and Central corneal thickness
Study on correlation between Diabetes mellitus and Central corneal thicknessStudy on correlation between Diabetes mellitus and Central corneal thickness
Study on correlation between Diabetes mellitus and Central corneal thickness
 
Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...
Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...
Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...
 
Dr screening training for nurses 1-diabetic retinopathy screening programs,...
Dr screening training for nurses   1-diabetic retinopathy screening programs,...Dr screening training for nurses   1-diabetic retinopathy screening programs,...
Dr screening training for nurses 1-diabetic retinopathy screening programs,...
 
Glaucoma
GlaucomaGlaucoma
Glaucoma
 
MG comparison, Ocular vs General
MG comparison, Ocular vs GeneralMG comparison, Ocular vs General
MG comparison, Ocular vs General
 
Glaucoma the-silent-thief of sight by Abdulwahab Usman
Glaucoma the-silent-thief of sight by Abdulwahab UsmanGlaucoma the-silent-thief of sight by Abdulwahab Usman
Glaucoma the-silent-thief of sight by Abdulwahab Usman
 
Glaucoma suspect,ocular hypertension, steroid induced glaucoma
Glaucoma suspect,ocular hypertension, steroid induced glaucomaGlaucoma suspect,ocular hypertension, steroid induced glaucoma
Glaucoma suspect,ocular hypertension, steroid induced glaucoma
 
Gruber R, I Fetian et al. The Effect of Magnesium on RVP of Patients with NTG...
Gruber R, I Fetian et al. The Effect of Magnesium on RVP of Patients with NTG...Gruber R, I Fetian et al. The Effect of Magnesium on RVP of Patients with NTG...
Gruber R, I Fetian et al. The Effect of Magnesium on RVP of Patients with NTG...
 
Glaucoma
GlaucomaGlaucoma
Glaucoma
 

Recently uploaded

JOURNAL CLUB PRESENTATION TEMPLATE DOCUMENT
JOURNAL CLUB PRESENTATION TEMPLATE DOCUMENTJOURNAL CLUB PRESENTATION TEMPLATE DOCUMENT
JOURNAL CLUB PRESENTATION TEMPLATE DOCUMENTThomas Onyango Kirengo
 
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS by Dr M.KARTHIK EMMANUEL
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS  by Dr M.KARTHIK EMMANUELCONGENITAL HYPERTROPHIC PYLORIC STENOSIS  by Dr M.KARTHIK EMMANUEL
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS by Dr M.KARTHIK EMMANUELMKARTHIKEMMANUEL
 
DR. Neha Mehta Best Psychologist.in India
DR. Neha Mehta Best Psychologist.in IndiaDR. Neha Mehta Best Psychologist.in India
DR. Neha Mehta Best Psychologist.in IndiaNehamehta128467
 
ANAPHYLAXIS BY DR.SOHAN BISWAS,MBBS,DNB(INTERNAL MEDICINE) RESIDENT.pptx
ANAPHYLAXIS BY DR.SOHAN BISWAS,MBBS,DNB(INTERNAL MEDICINE) RESIDENT.pptxANAPHYLAXIS BY DR.SOHAN BISWAS,MBBS,DNB(INTERNAL MEDICINE) RESIDENT.pptx
ANAPHYLAXIS BY DR.SOHAN BISWAS,MBBS,DNB(INTERNAL MEDICINE) RESIDENT.pptxDr. Sohan Biswas
 
Treatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas HospitalTreatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas HospitalGokuldas Hospital
 
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose AcademicsConnective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose AcademicsMedicoseAcademics
 
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...JRRolfNeuqelet
 
Quality control tests of suppository ...
Quality control tests  of suppository ...Quality control tests  of suppository ...
Quality control tests of suppository ...Hasnat Tariq
 
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATROROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATROKanhu Charan
 
How to buy 5cladba precursor raw 5cl-adb-a raw material
How to buy 5cladba precursor raw 5cl-adb-a raw materialHow to buy 5cladba precursor raw 5cl-adb-a raw material
How to buy 5cladba precursor raw 5cl-adb-a raw materialSherrylee83
 
Video capsule endoscopy (VCE ) in children
Video capsule endoscopy (VCE ) in childrenVideo capsule endoscopy (VCE ) in children
Video capsule endoscopy (VCE ) in childrenRaju678948
 
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose AcademicsCytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose AcademicsMedicoseAcademics
 
^In Pietermaritzburg Hager Werken Embalming +27789155305 Compound Powder in ...
^In Pietermaritzburg  Hager Werken Embalming +27789155305 Compound Powder in ...^In Pietermaritzburg  Hager Werken Embalming +27789155305 Compound Powder in ...
^In Pietermaritzburg Hager Werken Embalming +27789155305 Compound Powder in ...pinkpowder997723
 
Overview on the Automatic pill identifier
Overview on the Automatic pill identifierOverview on the Automatic pill identifier
Overview on the Automatic pill identifierNidhi Joshi
 
Sonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptxSonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptxpalsonia139
 
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالةGallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالةMohamad محمد Al-Gailani الكيلاني
 
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...marcuskenyatta275
 
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019Akash Agnihotri
 
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depthsUnveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depthsYash Garg
 

Recently uploaded (20)

JOURNAL CLUB PRESENTATION TEMPLATE DOCUMENT
JOURNAL CLUB PRESENTATION TEMPLATE DOCUMENTJOURNAL CLUB PRESENTATION TEMPLATE DOCUMENT
JOURNAL CLUB PRESENTATION TEMPLATE DOCUMENT
 
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS by Dr M.KARTHIK EMMANUEL
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS  by Dr M.KARTHIK EMMANUELCONGENITAL HYPERTROPHIC PYLORIC STENOSIS  by Dr M.KARTHIK EMMANUEL
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS by Dr M.KARTHIK EMMANUEL
 
DR. Neha Mehta Best Psychologist.in India
DR. Neha Mehta Best Psychologist.in IndiaDR. Neha Mehta Best Psychologist.in India
DR. Neha Mehta Best Psychologist.in India
 
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
 
ANAPHYLAXIS BY DR.SOHAN BISWAS,MBBS,DNB(INTERNAL MEDICINE) RESIDENT.pptx
ANAPHYLAXIS BY DR.SOHAN BISWAS,MBBS,DNB(INTERNAL MEDICINE) RESIDENT.pptxANAPHYLAXIS BY DR.SOHAN BISWAS,MBBS,DNB(INTERNAL MEDICINE) RESIDENT.pptx
ANAPHYLAXIS BY DR.SOHAN BISWAS,MBBS,DNB(INTERNAL MEDICINE) RESIDENT.pptx
 
Treatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas HospitalTreatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas Hospital
 
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose AcademicsConnective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
 
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
 
Quality control tests of suppository ...
Quality control tests  of suppository ...Quality control tests  of suppository ...
Quality control tests of suppository ...
 
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATROROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
 
How to buy 5cladba precursor raw 5cl-adb-a raw material
How to buy 5cladba precursor raw 5cl-adb-a raw materialHow to buy 5cladba precursor raw 5cl-adb-a raw material
How to buy 5cladba precursor raw 5cl-adb-a raw material
 
Video capsule endoscopy (VCE ) in children
Video capsule endoscopy (VCE ) in childrenVideo capsule endoscopy (VCE ) in children
Video capsule endoscopy (VCE ) in children
 
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose AcademicsCytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
 
^In Pietermaritzburg Hager Werken Embalming +27789155305 Compound Powder in ...
^In Pietermaritzburg  Hager Werken Embalming +27789155305 Compound Powder in ...^In Pietermaritzburg  Hager Werken Embalming +27789155305 Compound Powder in ...
^In Pietermaritzburg Hager Werken Embalming +27789155305 Compound Powder in ...
 
Overview on the Automatic pill identifier
Overview on the Automatic pill identifierOverview on the Automatic pill identifier
Overview on the Automatic pill identifier
 
Sonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptxSonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptx
 
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالةGallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
 
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
 
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
 
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depthsUnveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
 

CCT and TARGET PRESSURE in Glaucoma Management - Pfizer Symposium.pptx

  • 1. EVIDENCE-BASED DECISION MAKING IN GLAUCOMA MANAGEMENT ROLE OF TARGET PRESSURE AND CENTRAL CORNEAL THICKNESS By Dr Nkiru Kizor-Akaraiwe @ South-East Glaucoma symposium Feb, 2017
  • 2. Background • IOP is a very important risk factor • IOP is the only modifiable risk factor • Aim of glaucoma Rx is to maintain visual function(by reducing the IOP to such a level that glaucomatous damage will not continue) while maintaining quality of life at a sustainable cost. Treatment Principles & Options. EGS Guidelines, Edition 4. Pg 131-138
  • 3. Evidence – Based Care for IOP reduction in glaucoma Mx…… The Collaborative Normal-Tension Glaucoma Study Collaborative Normal-Tension Glaucoma Study Group(CNGTS). Effectiveness of intraocular pressure reduction in the treatment of normal- tension glaucoma. Am J Ophthalmol 1998;126:498-505
  • 4. Evidence – Based Care for IOP reduction in glaucoma Mx…… The Advanced Glaucoma Intervention Study Collaborative Normal-Tension Glaucoma Study Group(CNGTS). Effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998;126:498-505
  • 5. Evidence – Based Care for IOP reduction in glaucoma Mx…… The Collaborative Initial Glaucoma Treatment Study Musch DC, Gillespie BW, Niziol LM, et al; the CIGTS Study Group. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2011;118:1766-1773.
  • 6. Evidence – Based Care for IOP reduction in glaucoma Mx…… The Ocular Hypertension Treatment Study Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open- angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713.
  • 7. Evidence – Based Care for IOP reduction in glaucoma Mx…… Early Manifest Glaucoma Trial Heijl A, Leske MC, Bengtsson B, et al; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268-1279.
  • 8. What is Target pressure? • Target pressure is defined as the upper limit of IOP level at which further glaucomatous optic neuropathy is unlikely to occur inorder to maintain patient’s vision related quality of life. • Target pressure is the IOP goal • 1st introduced in 1989 by Paul F. Palmberg Treatment Principles & Options. EGS Guidelines, Edition 4. Pg 131-138
  • 9. Benefits of Target pressure in Mx 1. Gives the Physician a focus(goal) in care (No ‘continue Rx’) 2. Gives patient a focus and wish to keep their follow-up appointments 3. Gives the patients a goal that makes them take responsibility for their care & progress 4. Helps patients to appreciate success and non- success and more agreeable to a change of therapy (including surgery) Inder Paul Singh. Setting Target Pressures. Glaucoma Today. September/October 2015
  • 10. Setting Target IOP – Factors to consider Factors to Consider Low Target IOP Higher Target IOP 1. Glaucoma Damage Advanced Early 2. Life expectancy Long Short 3. Baseline (Untreated) IOP Low High 4. Additional Risk factors Yes No 5. Rate of Progression Fast Slow 6. CCT Thin Thick Treatment Principles & Options. EGS Guidelines, Edition 4. Pg 131-138
  • 11. Risk factors for progression that may modify the initial target IOP range include the following: • Presence and severity of damage to fellow eye • Rapid rate of progression of damage to fellow eye • Family history of or genetic mutation predisposing to early onset disease or severe disease, or both • African ancestry • Vascular risk factors: disc hemorrhage, nocturnal hypotension, migraine, Raynaud's disease, diabetes mellitus, previous vein occlusion • Large fluctuation or instability in IOP (e.g., IOP spikes, pseudoexfoliation syndrome) • Poor follow-up • Axial myopia (speculative) Damji KF, Behki R, Wang L, for the Target IOP Workshop participants. Canadian perspectives in glaucoma management: setting target intraocular pressure range. Can J Ophthalmol 2003;38:189-197.
  • 12. Setting Target IOP – Numbers or Percentages? Stage of Glaucoma Evidence IOP percentage reduction Range of IOP Findings from study OHTN OHTS ≥20% 18-21mmHg 5% progression at 20% reduction Mild Glaucoma EMGT CIGTS ≥25% < 18mmHg 30% reduction no progression in 7yrs Moderate Glaucoma CIGTS AGIS ≥30% 14-16mmHg Severe Glaucoma AGIS ≥35% 10- 12mmHg IOP average =12;no progression x 14yrs
  • 13. Principle for Setting Target pressure: IOP TgP = ------------------------------------------------ Level of function loss + RoP + Factors Treatment Principles & Options. EGS Guidelines, Edition 4. Pg 131-138
  • 14. Target pressure ….Points to note • Always note down in the folder the set target pressure with date. • Target pressure is set separately for each eye • Refer to it each visit – result of visit’s evaluation. • Not static - change constantly depending on whether the glaucoma is stable or shows signs of progression.
  • 16. Background • IOP is a very important risk factor • IOP is the only modifiable risk factor • IOP is measured by either indenting or applanating the central cornea therefore its thickness will affect the reading. Treatment Principles & Options. EGS Guidelines, Edition 4. Pg 131-138
  • 17. Evidence – Based Care for CCT measurement in glaucoma Mx…… The Ocular Hypertension Treatment Study Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713.
  • 18. CCT Values • The normal distribution of CCT is 540µm ± 30 • Blacks generally have thinner corneas • Screening population of normals @ The Eye Specialists hospital, Enugu, Nigeria = 526µm ± 75 (Range of 458-608) Rahman ML, Bunce C, Healey PR et al. Commingling analyses of central corneal thickness and adjusted intraocular pressure in an older Australian population. Invest Ophthalmol Vis Sci 2010;51(5) 2512-8
  • 19. CCT differences among patient groups • The mean central corneal thickness was: » Controls = 554 µm » POAG = 550 µm » NTG = 514 µm - lowest » OHT = 580 µm Shah S, Chatterjee A, Mathai M, et al. Relationship between corneal thickness and measured intraocular pressure in a general ophthalmology clinic. Ophthalmology. 1999;106:2154-2160. Copt RP, Thomas R, Mermoud A. Corneal thickness in ocular hypertension, primary open-angle glaucoma, and normal tension glaucoma. Arch Ophthalmol. 1999;117:14-16.
  • 20. Differences among Diff races Findings: • Caucasians, Chinese, Filipinos & Hispanics = 0.550mm > Japanese = 0.531mm > African Americans = 0.521mm Central corneal thickness of Caucasians, Chinese, Hispanics, Filipinos, African Americans, and Japanese in a glaucoma clinic. Aghaian E1, Choe JE, Lin S, Stamper RL. Ophthalmology 2004 Dec;111(12):2211-9
  • 21. Why is CCT important? • A Risk factor • Misdiagnosis • Uncertain-target pressure setting
  • 22. CCT as a Risk Factor • For development: The Ocular Hypertension Treatment Study (OHTS) showed that CCT is an important risk factor for a change from ocular hypertension to primary open-angle glaucoma. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713.
  • 23. CCT & POAG development • Subjects with CCT ≤ 555 µm had 3x greater risk of developing POAG than Those with CCT ≥ 588 µm Gordon MO, Beiser JA, Brandt JD, et al. The ocular hypertension treatment study: Baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714-720.
  • 24. CCT as a Risk Factor • For progression: Powerful predictor of risk of glaucoma progression - Early Manifest Glaucoma Trial (EMGT) with an 11- year follow-up, CCT was a significant predictive factor for glaucoma progression - In a multivariate model study in Advanced glaucoma pts by Weizer et al that included IOP, CCT was the most powerful component of the predictive model. Weizer JS, Stinnett SS, Herndon LW. Central corneal thickness as a risk factor for advanced glaucoma damage. Paper presented at: Annual Meeting of The Association for Research in Vision and Ophthalmology; May 5, 2003; Fort Lauderdale, FL. Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268-1279.Heijl A, Leske MC, Bengtsson B, et al; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression
  • 25. CCT & Progression Findings: • Eyes with CCT 520 m had significantly earlier glaucoma progression though the mean IOP was less in them. • Chiseliţă D1, Danielescu C, Gagos-Zaharia O, Gherman C. Central thickness of the cornea in ocular hypertension and open angle glaucoma Oftalmologia.2007;51(3):98-103
  • 26. 2. Mis-diagnosis of glaucoma • Variations in measurement of CCT may lead to mis-diagnosis of glaucoma. • Thin CCT  Underestimation of IOP/Target IOP - Glaucoma patients are missed/suspects - POAG classified as NTG • Thick CCT  Overestimation of IOP/ Target IOP - Normal patients receiving Rx as OHT - NTG managed as POAG
  • 27. The role of central corneal thickness in the diagnosis of glaucoma Result: 39% of eyes with ocular hypertension were found to have a corrected IOP of ≤ 21 mmHg. Thomas R, Korah S, Muliyil J. India J Ophthalmol 2000 Jun;48(2):107-11
  • 28. 3. Uncertain estimation of Target pressure • Low CCT  wrongly set higher TgP E.g CCT = 480µm (+4); TgP = 12mmHg instead of <9mmHg • High CCT  wrongly set Lower TgP E.g CCT 590µm (-4); TgP = 12 instead of <16mmHg
  • 29. The importance of central corneal thickness measurements and decision making in general ophthalmology clinics: a masked observational study Result: • CCT and adjusted IOP information led to different treatment option in 37%(55/152). - 20.4%(31/152) cases would have been commenced on additional IOP-lowering medication - 2.0%(3/152) would have been counseled for trabeculectomy surgery - 3.3%(5/152) of the cohort would have been observed rather than treated Patwardhan et al; BMC Ophthalmology2008;8:1 DOI: 10.1186/1471-2415-8-1
  • 30. Central corneal thickness and potential error in Goldmann applanation tonometry of the Black African patient suffering from primary open- angle glaucoma: 340 eyes surveyed. Findings: • GAT- affected by an error rate estimated at 69.4% - 57.6% undervaluation - 11.8% overvaluation • Pachymetry is therefore a necessity for the Black African glaucoma patient requiring IOP adjustment. • Fanny et al..J Fr Ophthalmol 2008 Apr;31(4):405-8
  • 31. Conclusion… • Target Pressure is the IOP goal set at beginning that drives the glaucoma care & • CCT measurement (Pachymetry) is an essential part of glaucoma pt’s evaluation for determining the real target pressure, predicting risk of development & progression of disease thereby ensuring individual pt’s optimal management.